New drug combo aims to stop nasopharyngeal cancer from returning
NCT ID NCT05201859
First seen May 08, 2026 · Last updated May 08, 2026
Summary
This study tests whether adding the immunotherapy drug sintilimab to the chemotherapy drug capecitabine can help prevent nasopharyngeal cancer from coming back after initial treatment. About 150 adults with advanced-stage disease who did not respond well to induction chemotherapy will receive either the combination or capecitabine alone. The goal is to see if the combination improves the time patients live without their cancer returning.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.